Medicaid fuels US coverage of Novo, Lilly weight-loss drugs
Portfolio Pulse from
U.S. government health plans are the primary source of coverage for new weight-loss drugs from Novo Nordisk and Eli Lilly, surpassing private insurers.
November 18, 2024 | 11:15 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Eli Lilly's weight-loss drugs are predominantly covered by U.S. government health plans, which could boost their sales and revenue.
The significant coverage by government health plans suggests increased accessibility and potential sales growth for Eli Lilly's weight-loss drugs, positively impacting revenue.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80